Symrise develops pure synthetic Cannabidiol for the Health Supplement market

Symrise has successfully developed nature-identical cannabinoid that is expected to revolutionise the pharmaceutical and food supplement market.
With Canapure® (cannabidiol), the pharmaceutical industry now has access to a nature-identical, synthetically produced CBD that is suitable both as a valuable active pharmaceutical ingredient and as an intermediate product for the development of new substances. Scientific studies prove that the nature-identical active ingredient is identical to CBD derived from the cannabis plant. At the same time, the new Symrise product achieves a purity level of 99.8%.
Symrise is setting new standards in the synthetic production of CBD. Canapure® is identical to natural CBD, which does not have psychoactive effects. It is said to have relaxing and anticonvulsive, anti-inflammatory, anxiety-relieving and nausea-relieving effects. THC derivatives are not detectable in this synthetic active ingredient.
A joint comparison study by the Universities of Madrid and Cordoba and specialised institutes in Spain and Germany confirms that analytics has found no significant difference in the biological value of purely natural CBD and nature-identical Canapure®.
“With Canapure®, we are offering a reliable alternative to natural CBD,” said Jörg Thilo Fischer; Technical Manager API at Symrise. “This product innovation is identical to natural CBD, of consistently high quality and purity and available year-round.”
Symrise uses D-limonene, which belongs to a group of terpenes, to produce Canapure®. This renewable raw material is a byproduct of the orange juice industry. It comes from the peels of the fruit. Symrise converts the D-limonene to menthadienol, which is ultimately used to produce Canapure®.
Symrise has also developed the synthetic CBD according to GMP guidelines for active ingredients for the pharmaceutical industry.